The global T-cell Lymphoma market size was valued at USD 6.65 Billion in 2022 and is projected to reach USD 34.83 Billion by 2031, expanding at a CAGR of 20.2% during the forecast period, 2023–2031. The growth of the market is attributed to the approval of Yescarta, Kymriah, and Tecartus and changing preference of organizations towards adoptive therapies.
Lymphoma is the most well-known blood disease. It happens when cells of the safe framework, called lymphocytes (a sort of white platelets), develop and increase wildly in the human body. Lymphoma is a kind of blood malignant growth that creates when white platelets called lymphocytes outgrow control.
Lymphocytes are important for your safe framework. They travel around your body in your lymphatic framework, assisting you with battling contaminations. There are two kinds of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells). Lymphomas can be assembled as Hodgkin lymphomas or non-Hodgkin lymphomas, contingent upon the kinds of cell they contain. Immune system microorganism lymphomas are non-Hodgkin lymphomas that create from T lymphocytes.
T Cell Lymphoma Market Trends, Drivers, Restraints, and Opportunities
-
Rising cases of lymphoma malignant growth because of radiations and increase in the quantity of T-cell lymphoma-explicit treatments are expected to boost the market during the forecast period.
-
Rapid growth in the adoption of premium-valued items like keytruda, opdivo, and insusceptible designated spot inhibitors and the launch of a several novel treatments with label expansion of commercialized items are estimated to boost the market during the forecast period.
-
Increasing focus on health treatment is expected to boost the market during the forecast period.
-
High price related with T-cell lymphoma treatment and the adverse symptoms of treatments are projected to hinder the market growth.
-
R&D investment and technological advancement in cancer immunotherapy is projected to create immense opportunities for market players.
Scope of T Cell Lymphoma Market Report
The report on the global T-cell lymphoma market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
T-cell lymphoma Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Types (Peripheral T-cell lymphoma(Cutaneous T-Cell lymphoma), and T-cell lymphoblastic lymphoma) and Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell therapy, and other types of therapy)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Novartis AG, Merck &Co. Inc., F.Hoffmann-La Roche Ltd, Bristol Myers Squibb Company, and Johnson & Johnson(Janssen Pharmaceuticals Inc.)
|
T Cell Lymphoma Market Segment Insights
The cutaneous T-cell lymphoma segment is projected to constitute a major market share
Based on types, the T-cell lymphoma market is bifurcated into peripheral T-cell lymphoma and cutaneous T-cell lymphoblastic lymphoma. The cutaneous T-cell lymphoma (CTCL) segment is expected to hold a key share of the market during the forecast period owing to yearly occurrence of CTCL is 0.4 to 1 case per 100,000 (or 1,000 to 3,000 new cases each year) in the US. Notwithstanding, death pace of CTCL isn't high and patients can live with CTCL around at least 10. The normal assessed commonness of CTCL in the U.S. is around 20,000. Consequently, this makes CTCL most predominant sort of immune system microorganism lymphoma. Adcertis makes PTCL one of the quickest developing T-cell lymphoma type markets.
The chemotherapy segment is expected to grow at a rapid pace
Based on therapy, the T-cell lymphoma market is segregated into chemotherapy, immunotherapy, radiotherapy, stem cell therapy, and other type of therapy. The chemotherapy segment is anticipated to hold major market share of market during the forecast period owing to the most well-known type of therapeutics used to stop the development of malignant cells. Medical procedure and radiation treatment works by eliminating, murdering, or harming the disease cells in a specific region, yet chemotherapy works all through the entire body, favorable reimbursement strategy for therapeutics medications make them accessible and reasonable.
For example, Pralatrexate is a chemotherapy drug that is utilized in the treatment of patients with stubborn fringe T-cell lymphoma (PTCL) is recorded under the PBS conspire by the Australian government. Subsequently, with the rising awareness about the advantages of chemotherapy and great government arrangements, the market is projected to boost during the forecast period.
North America is expected to hold a major market share
On the basis of regions, the T-cell lymphoma market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is anticipated to hold a major market share during the forecast period. Growth of the market is attributed to high prevalence of T-cell lymphoma, presence of key market players, and expanding research and development in the region. The presence of solid research, just as a commercial base combined with a high number of clinical preliminaries being led for T-cell treatments in the U.S., has significantly added to the predominance of the market in the region.
Besides, the expanding number of administrative endorsements in the U.S. furthermore, Canada alongside the changing reimbursement strategy in the area has likewise sped up the take-up of these treatments prompting huge market development. However, the market in North America is expected to exhibit a rapid growth in the coming years due to the presence of a considerable number of clinical focuses offering CAR-T cell treatments.
Segments
The global T-cell lymphoma market has been segmented on the basis of
Types
- Peripheral T-cells lymphoma (Cutaneous T-cell lymphoma)
- T-cells lymphoblastic lymphoma
Therapy
- Chemotherapy
- Radiotherapy
- Immunotherapy
- Stem Cell therapy
- Other types of therapy
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the T-cell lymphoma market include Novartis AG, Merck &Co. Inc., F. Hoffmann-La Roche Ltd, Bristol Myers Squibb Company, and Johnson & Johnson (Janssen Pharmaceuticals Inc.)
Some of these players have adopted several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
